...
首页> 外文期刊>Pediatric Pulmonology >Surfactant therapy in premature babies: SurE or InSurE
【24h】

Surfactant therapy in premature babies: SurE or InSurE

机译:早产儿的表面活性剂治疗:当然或保险

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background: Preterm infants with respiratory distress syndrome (RDS) requiring surfactant therapy have been traditionally receiving surfactant by intubation surfactant and extubation technique (InSurE), which comprises of tracheal intubation, surfactant administration, and extubation. However, more recently noninvasive methods like least invasive surfactant therapy or minimally invasive surfactant therapy have been reported to be successful. These methods, avoid intubation thus minimize airway trauma and avoid barotrauma. The primary aim of this randomized trial was to compare the need for mechanical ventilation (MV) between the administration of surfactant via a thin catheter during spontaneous breathing and the InSurE technique. Methods: Preterm infant's ≤34 weeks with RDS requiring continuous positive airway pressure (CPAP) within 6?hours of life were prospectively randomized to receive early surfactant either by SurE (surfactant without endotracheal tube intubation) or InSurE technique. The need for MV within the first 72?hours and other related outcomes were analyzed between the two groups. Results: One hundred seventy‐five infants in each group were analyzed. The need for MV in the first 72?hours of life was significantly lower in the SurE group compared to the InSurE group (19% vs 40%, P ??.01). Similarly, duration of oxygen therapy and hospital stay were significantly shorter in the SurE group. Furthermore, bronchopulmonary dysplasia (BPD) rate was significantly lower among the infants administered surfactant by the SurE technique. Conclusion: In preterm neonates with RDS who are stabilized on CPAP, the SurE technique for surfactant delivery results in the reduced need for MV and also may decrease the rate of BPD in some vulnerable subpopulations.
机译:摘要背景:具有表面活性剂治疗的呼吸窘迫综合征(RDS)的早产儿一直通过插管表面活性剂和拔管技术(保险)来接受表面活性剂,其包括气管插管,表面活性剂给药和拔管。然而,据报道,更近最近的非侵入性方法是最不侵入性表面活性剂治疗或微创表面活性剂治疗的成功。这些方法,避免插管,从而最大限度地减少了气道创伤,避免了巴罗拉姆。该随机试验的主要目的是在自发呼吸期间通过薄导管和保险技术进行比较表面活性剂的机械通气(MV)的需要。方法:早产儿≤34周的RDS需要连续正气道压力(CPAP)在6?小时内,通过肯定(没有气管内管插管的表面活性剂)或确保技术,以接受早期表面活性剂。在两组之间分析了在前72份的情况下对MV的需求和其他相关结果。结果:分析了每组七十五名婴儿。与保险组相比,在第一个72中对第一72次MV的需求在肯定的组中显着降低(19%vs 40%,p≤01)。同样,在肯定组中,氧疗法和住院住院的持续时间明显短。此外,通过肯定技术婴儿施用表面活性剂,支气管扩漏率(BPD)速率显着降低。结论:在稳定CPAP稳定的RDS的早产新生儿中,表面活性剂递送的肯定技术导致对MV的需求降低,并且还可以降低一些易受群体中的BPD率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号